Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-05-27 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
The Board of Directors of the Company at its meeting held today i.e., May 27, 2024, has inter-alia: 1. Approved the Audited financial results of the Company for the quarter and year ....
Regulatory Filings
2024-05-27 English
We wish to inform that at the meeting of Board of Directors of the Company held on May 27, 2024, the Board has recommended dividend of Rs. 24/- per equity share of Rs. 2/- each subject ....
Notice of Dividend Amount Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the Board of Directors' recommendation of a dividend for the financial year 2023-24. It mentions the dividend amount per share and that the dividend is subject to shareholder approval at the forthcoming AGM. The document does not contain financial statements or detailed financial data but is an announcement regarding dividend recommendation and payment details. Given the content and length (1180 characters), this fits the category of a Notice of Dividend Amount (DIV) rather than a full financial report or other filing types.
2024-05-27 English
Dividend Updates
Notice of Dividend Amount Classification · 100% confidence The document is a letter addressed to stock exchanges informing about the Board of Directors' recommendation of a dividend for the financial year 2023-24. It mentions the dividend amount per share and that the dividend is subject to shareholder approval at the forthcoming Annual General Meeting. The document is short (1180 characters) and serves as an announcement rather than a detailed report. There are no financial statements or detailed analysis present. This fits the category of a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts and payment details.
2024-05-27 English
Financial Result Updates
Regulatory Filings
2024-05-27 English
The Board of Directors of the Company at its meeting held today, i.e., May 27, 2024 has inter alia 1. Approved the audited financial results of the Company for the quarter and year ....
Regulatory Filings
2024-05-27 English
Dividend
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from AstraZeneca Pharma India Limited dated May 27, 2024, reporting the outcome of a Board Meeting. It includes approval of audited financial results for the quarter and year ended March 31, 2024, along with the audit report from statutory auditors. It also contains a press release with comprehensive financial performance highlights for the full fiscal year 2023-24, including revenue, profit before tax, earnings per share, and dividend recommendation. The document further discusses strategic collaborations, sustainability initiatives, recognitions, and company background. The presence of audited financial results and audit report, plus detailed financial data and analysis for the full fiscal year, indicates this is a full Annual Report or equivalent comprehensive financial disclosure. However, since it is not the full 10-K but an official announcement of audited results and includes the audit report, it fits best under Audit Report / Information (AR). It is not merely a brief earnings release or dividend notice, nor is it a regulatory filing or report publication announcement. Therefore, the classification is AR with high confidence. FY 2024
2024-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.